Evidence map›Paper›PMID 28587667›Full record

ArticleCardiovascular diabetology2017

The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes.

Trevor J Orchard, Bertrand Cariou, Margery A Connelly, James D Otvos, Shuyu Zhang, Caryl J Antalis, Tibor Ivanyi, Byron J Hoogwerf

4 registry-linked trialsOpen access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular diabetology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01435616 phase3completednot on this map

A Comparison of LY2605541 Versus Insulin Glargine as Basal Insulin Treatment in Combination With Oral Anti-Hyperglycemia Medications in Insulin-Naive Patients With Type 2 Diabetes Mellitus: A Double-Blind, Randomized Study

TypeinterventionalSponsorEli Lilly and CompanyRan2011 to 2014Enrolled1,538ConditionsDiabetes Mellitus, Type 2ArmsGlargine, LY2605541
NCT01454284 phase3completednot on this map

The Impact of LY2605541 Versus Insulin Glargine for Patients With Type 1 Diabetes Mellitus Treated With Preprandial Insulin Lispro: a Double-Blind, Randomized, 52-week Study

TypeinterventionalSponsorEli Lilly and CompanyRan2012 to 2014Enrolled1,114ConditionsDiabetes Mellitus, Type 1ArmsGlargine, LY2605541, Insulin Lispro
NCT01481779 phase3completednot on this map

The Impact of LY2605541 Versus Insulin Glargine for Patients With Type 1 Diabetes Mellitus Treated With Preprandial Insulin Lispro: An Open-Label, Randomized, 78-Week Study - The IMAGINE 1 Study

TypeinterventionalSponsorEli Lilly and CompanyRan2012 to 2014Enrolled455ConditionsDiabetes Mellitus, Type 1ArmsGlargine, LY2605541, Insulin Lispro
NCT01582451 phase3completednot on this map

A Comparison of LY2605541 Versus Insulin Glargine Alone or in Combination With Pre-study Oral Antihyperglycemic Medications in Patients With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin: An Open-Label, Randomized Study The IMAGINE 5 Study

TypeinterventionalSponsorEli Lilly and CompanyRan2012 to 2013Enrolled466ConditionsDiabetes Mellitus, Type 2ArmsLY2605541, Insulin glargine
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Trevor J OrchardDepartment of Epidemiology, GSPH, University of Pittsburgh, Pittsburgh, PA, USA.
Bertrand Carioul'Institut du Thorax, CHU Nantes INSERM, CNRS, UNIV Nantes, Nantes, France.
Margery A ConnellyLipoScience, Laboratory Corporation of America Holdings, Morrisville, NC, 27560, USA.
James D OtvosLipoScience, Laboratory Corporation of America Holdings, Morrisville, NC, 27560, USA.
Shuyu ZhangEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.
Caryl J AntalisEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.
Tibor IvanyiEli Lilly and Company, Budapest, 1075, Hungary.
Byron J HoogwerfEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA. hoogwerf_byron_james@lilly.com.
Eli Lilly (United States) · USLabCorp (United States) · USCentre National de la Recherche Scientifique · FRELI-HU Research and Development Non-Profit · HUUniversity of Pittsburgh · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn Phase 2/3 studies of basal insulin peglispro (BIL) compared to insulin glargine, patients with type 1 or type 2 diabetes previously treated with insulin and randomized to BIL had an increase in serum triglycerides (TGs). To further understand lipoprotein changes, a lipid substudy which included liver fat content was designed to assess relationships among the measured variables for each diabetes cohort and compare the hepato-preferential insulin BIL to glargine.

methodsIn three cohorts of patients with diabetes (type 1, type 2 insulin naïve, and type 2 previously on insulin; n = 652), liver fat content (LFC) was determined by magnetic resonance imaging (MRI) and blood lipids were analyzed by nuclear magnetic resonance (NMR) spectroscopy at baseline, 26 and 52 weeks of treatment. Apolipoproteins, adiponectin, and other lipid parameters were also measured. Descriptive statistics were done, as well as correlation analyses to look for relationships among LFC and lipoproteins or other lipid measures.

resultsIn patients with type 1 diabetes treated with BIL, but not glargine, small LDL and medium and large VLDL subclass concentrations increased from baseline. In patients with type 2 diabetes previously on insulin and treated with BIL, large VLDL concentration increased from baseline. In insulin naïve patients with type 2 diabetes treated with BIL, there were very few changes, while in those treated with glargine, small LDL and large VLDL decreased from baseline. Baseline LFC correlated significantly in one or more cohorts with baseline large VLDL, small LDL, VLDL size, and Apo C3. Changes in LFC by treatment showed generally weak correlations with lipoprotein changes, except for positive correlations with large VLDL and VLDL size. Adiponectin was higher in patients with type 1 diabetes compared to patients with type 2 diabetes, but decreased with treatment with both BIL and glargine.

conclusionsThe lipoprotein changes were in line with the observed changes in serum TGs; i.e., the cohorts experiencing increased TGs and LFC with BIL treatment had decreased LDL size and increased VLDL size. These data and analyses add to the currently available information on the metabolic effects of insulins in a very carefully characterized cohort of patients with diabetes. Clinicaltrials.gov registration numbers and dates NCT01481779 (2011), NCT01435616 (2011), NCT01454284 (2011), NCT01582451 (2012).

Indexed as

AdiposityMagnetic Resonance ImagingMagnetic Resonance SpectroscopyAdultAgedBiomarkersClinical Trials, Phase III as TopicDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2FemaleHumansHypoglycemic AgentsInsulin GlargineInsulin LisproLipoproteinsLiverbasal insulin peglisproBiomarkersHypoglycemic AgentsInsulin GlargineInsulin LisproLipoproteinsPolyethylene GlycolsAdiponectinApolipoproteinsBasal insulin peglisproDiabetesInsulin glargineLipoproteinsLiver fatMRINMR

Identifiers

PMID28587667
PMCPMC5461740
OpenAlexW2624352287

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.